Dyno Therapeutics is a biotechnology company that is focused on developing next-generation gene therapies using artificial intelligence (AI) and machine learning (ML) technologies. The company's proprietary platform enables the design of novel adeno-associated virus (AAV) vectors that can deliver gene therapies to specific cells and tissues in the body. Dyno's technology has the potential to significantly improve the efficacy and safety of gene therapies, and the company is currently developing treatments for a range of diseases, including rare genetic disorders, neurodegenerative diseases, and cancer.